The race to bring new tubeless insulin pumps to people with diabetes is intensifying, and Tandem Diabetes Care is now firmly in the mix. The company is developing Sigi, a reusable, rechargeable patch pump originally created by Swiss firm AMF Medical. While Tandem has not shared a release timeline, the device already carries FDA Breakthrough Device designation—a status that could accelerate U.S. clearance.

Tandem officially acquired AMF Medical in January 2023 for $216 million. At the time, CEO John Sheridan said AMF’s “compelling technology aligns well with our strategic vision to include a patch pump in Tandem’s portfolio of differentiated offerings.” Alongside the acquisition, Tandem gained Sigi’s intellectual property and AMF’s team of engineers, who had been refining the pump for several years.

What sets Sigi apart is its reusable design. Each user could receive two rechargeable pods, allowing one to be worn while the other charges. A disposable skin pad with a built-in cannula and pod attaches to the body, and the reusable piece locks into place on top. In an interview with Tandem, it was confirmed the pump will use prefilled 160-unit insulin cartridges—similar to those in smart pens—that can be swapped during pod sessions to reduce waste. Early reports suggest the pump is waterproof and more eco-friendly. We anticipate the device to incorporate Tandem’s recently FDA-cleared 7-day infusion set, an edge over the current three-days the Omnipod system and the upcoming Beta Bionics Mint would support.

Sigi is expected to run Tandem’s Control-IQ algorithm. The algorithm would run right on the pod itself, meaning it can keep dosing insulin even without a smartphone nearby. We anticipate the device to support both Dexcom and Abbott’s line of CGMs including its upcoming dual glucose-ketone sensor.

Sigi is just one piece of Tandem’s pipeline, and other products are expected sooner. The company is preparing to launch a tubeless option for Mobi, its smallest tubed insulin pump (read my 3-month review) along with the 7-day SteadiSet infusion set. Unlike Mobi, which is a hybrid design, Sigi was built as a tubeless-first platform from the ground up. Together, the two pumps give Tandem a chance to compete across both ends of the tubeless spectrum. For a broader look at what’s ahead, check out our roundup of seven next-gen insulin pumps and to learn more about Sigi, watch the video below.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.